EmSculpt NEO delivers two energies at once from the same applicator: a pulsed magnetic field that forces muscle to contract, and radiofrequency that heats tissue. Those two energies were cleared by the FDA under two different regulations, in two separate streams of paperwork, with two different sets of words.
The muscle claims sit under the powered muscle stimulator regulation. The fat claims sit under the radiofrequency regulation: They were granted at different times and they do not cover the same areas.
A 510(k) clearance means the FDA agreed a device is substantially equivalent to something already on the market. It is not a finding that the device works: Keep that in mind through everything below: what follows is a map of what the paperwork permits a company to say, not a map of what has been shown to happen.
One further caution about naming. BTL files with the FDA under model numbers, not trade names, and the FDA's own device records for the EmSculpt NEO brand name carry no submission number. So the wording quoted here is verbatim from specific filings by BTL Industries, but the link between any given filing and the machine branded EmSculpt NEO is an inference from the device descriptions, not something the FDA publishes.
The muscle-side filing dated 6 January 2021 reads, verbatim:
Improvement of abdominal tone, strengthening of the abdominal muscles, development of firmer abdomen.
Strengthening, toning and firming of buttocks, thighs and calves.
Improvement of muscle tone and firmness, for strengthening muscles in arms.
That is word for word the wording the HIFEM-only device already carried after July 2019: The muscle side of the NEO's paperwork added no new area and no new claim.
Two details are worth noticing in that text. The arm wording says "muscles in arms" — it does not name biceps or triceps, and no BTL filing carries a biceps- or triceps-specific indication. And nothing in the muscle list mentions fat, circumference or skin.
Later filings, in December 2023 and August 2024, added rehabilitation indications to this platform: relaxation of muscle spasms, prevention or retardation of disuse atrophy, increasing local blood circulation, muscle re-education, immediate post-surgical stimulation of calf muscles to prevent venous thrombosis, and maintaining or increasing range of motion. Those are medical indications used under medical supervision. They are not cosmetic area claims, and a clinic citing "new FDA clearance for medical conditions" is usually pointing at these.
The radiofrequency-side filings use completely different language: non-invasive lipolysis, meaning breakdown of fat, and reduction in circumference. The areas arrived one at a time.
Abdomen, 5 December 2019: Non-invasive lipolysis of the abdomen and reduction in circumference of the abdomen. Restricted to Fitzpatrick skin types I to III.
Thighs, 26 January 2021: The same two claims added for the thighs, still skin types I to III.
Skin types widened, 9 July 2021: The same abdomen and thigh claims, now covering Fitzpatrick skin types I to VI. That filing states there were no technological modifications to the device or applicator compared with the predicate — only the skin-type range changed.
Upper arms, 5 January 2022: Non-invasive lipolysis of the upper arms, limited to skin types II and III and BMI 30 or under. Note what is missing: there is no reduction-in-circumference claim for arms, only lipolysis.
Flanks, 21 September 2023: Non-invasive lipolysis of the flanks, limited to skin types I to IV.
Those restrictions are not clinic policy or marketing convention. They are inside the indication text the FDA cleared, which means they are the narrowest and most precise statements available about who each area claim applies to.
Put them side by side and the gaps are obvious.
Buttocks and calves carry muscle wording and no fat wording: No BTL filing retrieved gives EmSculpt NEO a fat-reduction or circumference claim for buttocks or calves. If you are being sold NEO to reduce fat on your buttocks, that is off-label use — which is legal and common, but it is not what the clearance says.
Flanks carry fat wording and no muscle wording: The flank claim is lipolysis only.
Abdomen and thighs carry both: They are the only two areas that do.
Upper arms carry a fat claim with two written restrictions and no circumference claim, and a muscle claim that covers "arms" generally.
There is also a mismatch with the marketing. BTL's own site lists ten treatable zones: abdomen, flanks, buttocks, front thighs, back thighs, outer thighs, inner thighs, arms, legs and back. Back and legs do not appear as cleared areas in any of the filings above. "Legs" is broader than "thighs and calves", and there is no back indication at all.
Clearance tells you what may be claimed. It says almost nothing about what has been measured. Here is the second list.
Abdomen — by far the strongest: One randomised sham-controlled trial of 72 people, measured by ultrasound, plus an open-label multicentre MRI study in 41 people reporting muscle 26.1 per cent thicker and fat 30.8 per cent thinner at three months. Also a re-analysis of 40 people showing visceral fat area down 17.8 per cent at three months.
Thighs — two studies, both open label, and they measured different things: One followed 16 women's inner thighs with MRI and reported fat down 27.4 per cent and muscle up 23.2 per cent at three months. The other enrolled 93 people for lateral thighs, imaged 51 at three months, and reported saddlebag fat down 18 plus or minus 5.5 mm with circumference down an average of 2.3 cm. That larger study reported fat only. It did not report thigh muscle change.
The study behind the thigh fat clearance missed its own responder target per person: 22 of 29 subjects reached the 1 cm goal against an 80 per cent bar. The detail is on the EmSculpt before and after thighs page.
Upper arms — one study: 34 enrolled, 25 imaged at three months by MRI: triceps 23.9 per cent thicker, fat 25.5 per cent thinner.
Buttocks — one two-arm non-randomised comparison: 27 people per arm at three months, MRI: 24.7 per cent muscle growth with the NEO against 15.9 per cent with HIFEM alone. Buttock fat is a different story. A gluteal MRI study of HIFEM found gluteal adipose tissue insignificantly affected, and a small NEO study of three people found buttock fat change negligible. The widely repeated claim of a 16 per cent fat reduction in the buttocks is contradicted by the actual gluteal MRI data, and no study reporting it could be located.
Flanks — one study, reporting oblique muscle thickness up 27.2 per cent and flank fat cross-sectional area down 30.5 per cent. The number of people treated is not stated in the abstract.
Calves — nothing: No published EmSculpt NEO study of calves could be located. The calf evidence in this whole field belongs to the HIFEM-only device and consists of two papers by the same author: a case study of two people, and an ultrasound study in which 13 of 20 participants had calves treated. A 2022 critical review counted 15 calf patients in the entire literature.
So the areas with a cleared claim and no NEO evidence are calves, and the area with a fat claim and the weakest supporting data is upper arms: Both are routinely sold.
Every EmSculpt NEO study named above except the sham-controlled trial is open label with no control group. An independent 2025 review of seven NEO studies found that all seven were authored by BTL medical advisors and that the measured changes were likely within the margin of error.
A separate review of 15 HIFEM studies found that none of them recorded patients' weight before and after treatment. In a four-week study of an area measured in millimetres, that is a large hole.
Ask which clearance your treatment sits under. If you are being treated for fat, the areas with fat wording are abdomen, thighs, flanks and upper arms. If it is for muscle, the areas are abdomen, buttocks, thighs, calves and arms. Anything else is off-label — permitted, but worth knowing.
If you are being treated on the upper arms for fat, ask about the two restrictions in that indication: Fitzpatrick skin types II and III, and BMI 30 or under.
BTL does not publish its instructions for use, so the manufacturer's own contraindication list is not publicly available. From the device class and FDA guidance: disclose in advance any implanted electronic device such as a pacemaker, defibrillator, neurostimulator or drug pump, and any metal implant that would sit in the treatment field. Disclose a hernia in or near the area — hernia is on the FDA's list of serious risks for this class and forceful involuntary contraction is the concern. Also disclose recent surgery in the area, broken skin or active infection, a bleeding disorder, a seizure disorder, or a cancer being treated in the field.
Fever with spreading redness, warmth or pus at a treated area. These are signs of a spreading infection and need urgent care the same day.
A blister or open, weeping burn on the treated skin.
A firm lump develops in a treated area and does not settle
Soreness keeps getting worse after about day three instead of easing
The skin over the treated area stays red, darkens, or feels numb for more than a few days
You were sold fat reduction on an area — buttocks or calves — that carries only muscle wording